Akari Therapeutics Plc
Open
$5.51
Prev. Close
$5.51
High
$5.51
Low
$5.41
Market Snapshot
$9.36M
-0.5
9
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 8 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
emptyResult
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 8 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Recently from Cashu
Akari Therapeutics Advances Nomacopan for Rare Autoimmune Diseases in Clinical Trials
Akari Therapeutics Advances Rare Disease Treatment with Innovative Therapies Akari Therapeutics Plc is actively developing a promising treatment approach for rare autoimmune diseases, particularly foc…
Please provide the text that you would like summarized, and I will create the title based on your requirements.
Please provide the text that you would like summarized, and I will create the article based on your requirements.
Akari Therapeutics' Innovative Approach Advances Autoimmune Disease Treatment with Nomacopan
Akari Therapeutics Advances in Autoimmune Disease Treatment with Novel Approach Akari Therapeutics Plc is making significant strides in the treatment of autoimmune diseases with its innovative drug pi…
Please provide the content you want summarized, and I'll create a title for you!
To provide a summary, I need the specific text you'd like me to condense. Please share the content you'd like summarized, and I'll be happy to help!